COST EFFECTIVENESS OF OVERACTIVE BLADDER TREATMENT WITH MIRABEGRON IN PATIENTS IN SOUTH KOREA

被引：0
作者：
Suh, D. [1 ]
Lee, S. [1 ]
Lim, S. J. [1 ]
Song, J. [1 ]
Ko, G. [2 ]
机构：
[1] Chung Ang Univ, Seoul, South Korea
[2] Astellas Pharma Inc, Seoul, South Korea
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.08.502
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK8
引用
收藏
页码：A847 / A847
页数：1
相关论文
共 50 条
  • [31] Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study)
    Alcantara-Montero, A.
    ACTAS UROLOGICAS ESPANOLAS, 2016, 40 (09): : 593 - 594
  • [32] NEUROSTIMULATION TREATMENT FOR OVERACTIVE BLADDER: AN EVALUATION OF COST EFFECTIVENESS DATA
    MacDiarmid, Scott
    Martinson, Melissa
    Black, Edward
    NEUROUROLOGY AND URODYNAMICS, 2013, 32 (02) : 112 - 112
  • [33] Optimizing quality of care and cost effectiveness in the treatment of overactive bladder
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2001, 7 (02) : S43 - S45
  • [34] COST EFFECTIVENESS OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER IN THE UNITED STATES
    Chen, J., V
    Klein, T. M.
    Mudd, P.
    VALUE IN HEALTH, 2021, 24 : S235 - S235
  • [35] Effectiveness and tolerability of mirabegron in children with overactive bladder: A retrospective pilot study
    Fryer, Samantha
    Nicoara, Cezar
    Dobson, Emily
    Griffiths, Megan
    McAndrew, H. Fiona
    Kenny, Simon E.
    Corbett, Harriet J.
    JOURNAL OF PEDIATRIC SURGERY, 2020, 55 (02) : 316 - 318
  • [36] NEUROSTIMULATION TREATMENT FOR OVERACTIVE BLADDER: AN EVALUATION OF COST EFFECTIVENESS DATA
    MacDiarmid, Scott
    Martinson, Melissa
    Black, Edward
    JOURNAL OF UROLOGY, 2012, 187 (04) : E478 - E478
  • [37] COST-EFFECTIVENESS OF TOLTERODINE AS TREATMENT FOR OVERACTIVE BLADDER (OAB) IN ADULT MEXICAN PATIENTS
    Arreola-Ornelas, H.
    Rosado-Buzzo, A.
    Garcia-Mollinedo, M.
    Camacho-Cordero, L.
    Mucino-Ortega, E.
    Mould-Quevedo, J. F.
    Galindo-Suarez, R. M.
    VALUE IN HEALTH, 2011, 14 (03) : A76 - A76
  • [38] The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial
    Moussa, Mohamad
    Abou Chakra, Mohamad
    Dabboucy, Baraa
    Fares, Youssef
    Dellis, Athanasios
    Papatsoris, Athanasios
    SCANDINAVIAN JOURNAL OF UROLOGY, 2022, 56 (01) : 66 - 72
  • [39] Supplementary data: Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada
    Herschorn, Sender
    Nazir, Jameel
    Ramos, Barbara
    Hakimi, Zalmai
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (3-4): : E129 - E133
  • [40] Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?
    Manami Kinjo
    Kazuki Masuda
    Yu Nakamura
    Satoru Taguchi
    Mitsuhiro Tambo
    Hiroshi Fukuhara
    International Urogynecology Journal, 2023, 34 : 853 - 859
12345